Hims & Hers Health earnings release, August 10, 2026

Hims & Hers Health, Inc. (HIMS) · Form 8-K, Item 2.02 · Filed · SEC filing

Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026

Subscribers grew to nearly 2.9 million, up 19% year-over-year in Q2 2026

Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million

SAN FRANCISCO, August 10, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second quarter ended June 30, 2026.

“Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care. We’re proving, quarter after quarter, that helping people feel great and delivering strong results aren’t mutually exclusive,” said Andrew Dudum, co-founder and CEO. “We have never been better positioned to move faster or go further than we are today. As we rebuild the consumer health experience from the ground up with a doctor-led AI clinical engine, the depth and breadth of our relationships with customers worldwide has never been greater. Every quarter, we raise the standard for what care should look like everywhere: high-quality, personal, and accessible.”

“Our second quarter results were defined by a significant re-acceleration in our growth profile and the continued expanding reach of our platform,” said Yemi Okupe, Chief Financial Officer. “Domestic revenue growth accelerated to 16% year-over-year, and our international business grew more than 17-fold, strengthened by the close of our Eucalyptus acquisition in June. We expect our domestic business to continue accelerating through the second half of the year. This momentum, combined with the meaningful efficiencies we're generating from our investments in AI and technology, positions us to make access to high touch, comprehensive care more affordable for our customers while also significantly expanding our reach internationally. As a result, we are raising our 2026 revenue outlook and building increased conviction in our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.”

Key Business Metrics

(In Thousands, Except for Monthly Revenue per Average Subscriber, Unaudited)

Revenue

(In Thousands, Unaudited)

Second Quarter 2026 Financial Highlights

• Revenue was $753.2 million for the second quarter of 2026 compared to $544.8 million for the second quarter of 2025, an increase of 38% year-over-year.

• Gross margin was 64% for the second quarter of 2026 compared to 76% for the second quarter of 2025.

• Net loss was $86.3 million for the second quarter of 2026 compared to net income of $42.5 million for the second quarter of 2025.

• Adjusted EBITDA was $60.3 million for the second quarter of 2026 compared to $82.2 million for the second quarter of 2025.

• Net cash (used in) operating activities was

$(35.9) million for the second quarter of 2026 compared to $(19.1) million for the second quarter of 2025.

• Free Cash Flow was $(68.2) million for the second quarter of 2026 compared to $(69.4) million for the second quarter of 2025.

Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net (loss) income and net cash (used in) provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States (“U.S. GAAP”), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers is providing the following guidance:

For the third quarter 2026, we expect:

• Revenue of $880 million to $900 million.

• Adjusted EBITDA of $75 million to $95 million, reflecting an Adjusted EBITDA margin of 9% to 11%.

For the full year 2026, we expect:

• Revenue of $3.1 billion to $3.3 billion.

• Adjusted EBITDA of $275 million to $325 million, reflecting an Adjusted EBITDA margin of 9% to 10%.

Financial statements

Income Statement

Three Months Ended June 30, — (In Thousands, Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Three Months Ended June 30, – % ChangeSix Months Ended June 30, – 2026Six Months Ended June 30, – 2025Six Months Ended June 30, – % Change
United States Revenue621,830537,28616.0%1,151,7391,115,9783.0%
Rest of the World Revenue131,3847,5471641.0%209,57914,8651310.0%
Total revenue753,214544,83338.0%1,361,3181,130,84320.0%

Income Statement

Three Months Ended June 30, — (In Thousands, Except Share and Per Share Data, Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue753,214544,8331,361,3181,130,843
Cost of revenue272,411128,637483,728283,958
Gross profit480,803416,196877,590846,885
Gross margin %64.0%7664.0%75
Operating expenses:(1)Marketing262,236217,862484,239449,097
Operating expenses:(1)Operations and support95,48166,490191,984129,523
Operating expenses:(1)Technology and development54,90137,848101,83767,762
Operating expenses:(1)General and administrative165,37767,273275,045115,883
Operating expenses:(1)Total operating expenses577,995389,4731,053,105762,265
Operating expenses:(1)(Loss) income from operations-97,19226,723-175,51584,620
Other income (expense):Change in fair value of equity securities4,737-4,945
Other income (expense):Change in fair value of liabilities-4,223-21,869
Other income (expense):Other income, net4,0456,1308,1458,728
Other income (expense):Total other income (expense), net4,5596,130-18,6698,728
Other income (expense):(Loss) income before income taxes-92,63332,853-194,18493,348
Other income (expense):Benefit from (provision for) income taxes6,3439,65215,779-1,358
Other income (expense):Net (loss) income-86,29042,505-178,40591,990
Other income (expense):Other comprehensive (loss) income-41,632986-48,3311,146
Other income (expense):Total comprehensive (loss) income-127,92243,491-226,73693,136
Net (loss) income per share attributable to common stockholders:Basic-0.370.19-0.780.41
Net (loss) income per share attributable to common stockholders:Diluted-0.370.17-0.780.37
Weighted average shares outstanding:Basic231,746,126224,373,375230,061,076223,187,936
Weighted average shares outstanding:Diluted231,746,126256,779,292230,061,076251,894,929

Income Statement

Three Months Ended June 30, — (In Thousands, Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue753,214544,8331,361,3181,130,843
Net (loss) income-86,29042,505-178,40591,990
Legal contingencies47,50062,500
Stock-based compensation42,11635,72678,97860,584
Depreciation and amortization29,47710,46551,43018,741
Acquisition and transaction-related costs28,8356,23142,2016,255
Restructuring and other related charges4,62638,114
Change in fair value of liabilities4,22321,869
Payroll tax expense related to stock-based compensation2,0223,0784,8893,078
Impairment of long-lived assets1,1481,148
Interest income and expense, net-2,254-6,117-7,287-8,713
Change in fair value of equity securities-4,7374,945
(Benefit from) provision for income taxes-6,343-9,652-15,7791,358
Adjusted EBITDA60,32382,236104,603173,293
Net (loss) income as a % of revenue-118-138
Adjusted EBITDA margin815815

Income Statement

Three Months Ended June 30, — (In Thousands, Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue753,214544,8331,361,3181,130,843
Gross Profit480,803416,196877,590846,885
Restructuring and other related charges included within cost of revenue28,462
Adjusted Gross Profit480,803416,196906,052846,885
Gross margin %64766475
Adjusted gross margin %64766775

Balance Sheet

June 30, 2026 — (In Thousands, Except Share and Per Share Data, Unaudited)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents609,811228,616
Current assets:Short-term available-for-sale investments231,237348,876
Current assets:Receivables, net375,29132,149
Current assets:Inventory87,78180,128
Current assets:Prepaid expenses and other current assets80,49377,869
Current assets:Total current assets1,384,613767,638
Current assets:Long-term available-for-sale investments351,263
Current assets:Goodwill1,101,720278,325
Current assets:Property, equipment, and software, net364,215311,930
Current assets:Intangible assets, net422,809196,116
Current assets:Operating lease right-of-use assets165,565137,046
Current assets:Deferred tax assets, net111,57882,707
Current assets:Other long-term assets78,31429,680
Current assets:Total assets3,628,8142,154,705
Current liabilities:Accounts payable501,297143,278
Current liabilities:Accrued liabilities210,25577,039
Current liabilities:Deferred revenue141,384127,160
Current liabilities:Deferred acquisition payable537,3811,479
Current liabilities:Earn-out consideration81,36450,632

Cash Flow

Six Months Ended June 30, — (In Thousands, Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating activitiesNet (loss) income-178,40591,990
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Depreciation and amortization51,43018,741
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Stock-based compensation78,97860,584
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Change in fair value of equity securities4,945
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Change in fair value of liabilities21,869
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Net accretion on securities-338-1,060
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Benefit from deferred taxes-23,338-10,346
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Impairment of long-lived assets1,148
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Amortization of debt discount and issuance costs3,6561,047
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Non-cash operating lease cost9,4824,594
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Non-cash acquisition-related costs21,3112,985
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Non-cash restructuring and other related charges included within cost of revenue28,462
Adjustments to reconcile net (loss) income to net cash provided by operating activities:Non-cash other2,511-1,315
Changes in operating assets and liabilities:Receivables, net-328,987-654
Changes in operating assets and liabilities:Inventory-14,255-77,373
Changes in operating assets and liabilities:Prepaid expenses and other current assets80-37,427
Changes in operating assets and liabilities:Other long-term assets-30,553-10
Changes in operating assets and liabilities:Accounts payable323,7955,146
Changes in operating assets and liabilities:Accrued liabilities89,52611,737
Changes in operating assets and liabilities:Deferred revenue2,96023,132
Changes in operating assets and liabilities:Earn-out consideration-7,058
Changes in operating assets and liabilities:Deferred acquisition payable472
Changes in operating assets and liabilities:Operating lease liabilities-4,894-1,798
Changes in operating assets and liabilities:Other long-term liabilities620
Changes in operating assets and liabilities:Net cash provided by operating activities53,41789,973
Investing activitiesMaturities of available-for-sale investments116,23260,569
Investing activitiesProceeds from sales of available-for-sale investments350,762
Investing activitiesPurchases of property, equipment, and intangible assets-55,770-101,392
Investing activitiesInvestment in website development and internal-use software-12,808-7,961
Investing activitiesAcquisition of businesses, net of cash acquired-318,108-5,100
Investing activitiesPurchases of equity securities-11,217
Investing activitiesNet cash provided by (used in) investing activities69,091-53,884
Financing activitiesProceeds from issuance of convertible senior notes, net of debt discount390,425970,000
Financing activitiesPurchases of capped calls related to convertible senior notes-36,748-47,800
Financing activitiesProceeds from exercise of vested stock options13,0306,497
Financing activitiesPayments for taxes related to net share settlement of equity awards-62,324-62,475
Financing activitiesProceeds from employee stock purchase plan3,8462,970
Financing activitiesPayments for acquisition-related earn-out consideration-43,682
Financing activitiesPayments for debt issuance costs-671-3,041
Financing activitiesNet cash provided by financing activities263,876866,151
Financing activitiesForeign currency effect on cash and cash equivalents-5,1891,270
Financing activitiesIncrease in cash, cash equivalents, and restricted cash381,195903,510
Financing activitiesCash, cash equivalents, and restricted cash at beginning of period228,616221,440

Cash Flow

Three Months Ended June 30, — (In Thousands, Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net cash (used in) provided by operating activities-35,939-19,11753,41789,973
Purchases of property, equipment, and intangible assets in investing activities-25,926-46,065-55,770-101,392
Investment in website development and internal-use software in investing activities-6,328-4,250-12,808-7,961
Free Cash Flow-68,193-69,432-15,161-19,380
Full release

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the second quarter 2026 results on August 10, 2026, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for international participants, and referencing conference ID #782 611 911. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health.... (truncated)why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit investors.hims.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions; changes in our product or offering mix, and the timing and market acceptance of any new products or offerings; the timing and anticipated effect of any pending or recently completed acquisitions; the success and utility of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of August 10, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most... (truncated) 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

Our consolidated revenue primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services, primarily consisting of medical consultation services, membership-based access, post-consultation service support, and delivery of laboratory testing results, as applicable. Our online sales are net of refunds, credits, and chargebacks, and include revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. A substantial majority of our online sales are subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. This revenue also includes sales from customers who have made one-time purchases.

“United States Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.

“Rest of the World Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.

“Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.

“Monthly Revenue per Average Subscriber” is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period.

“Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Hims & Hers Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.